Enhancing the anticancer effect of the histone deacetylase inhibitor by activating transglutaminase

European Journal of Cancer

Volumn 48, Issue 17, 2012, Pages 3278-3287

  Ling, Dora ^a   Marshall, Glenn M ^a,b   Liu, Pei Y ^a   Xu, Ning ^a   Nelson, Charlotte A ^a   Iismaa, Siiri E ^c   Liu, Tao ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b SYDNEY CHILDREN'S HOSPITAL   (Australia)

^c VICTOR CHANG CARDIAC RESEARCH INSTITUTE   (Australia)

Author keywords

Histone deacetylase inhibitor; Neuroblastoma; Transglutaminase activator

Indexed keywords

NARINGENIN; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE; VORINOSTAT;

AMIDATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER PATIENT; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG POTENTIATION; ENZYME ACTIVATION; ENZYME INDUCTION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MOUSE; NEUROBLASTOMA CELL; NONHUMAN; ONCOGENE C MYB; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSCRIPTION INITIATION; TRANSGENIC MOUSE; TUMOR GROWTH;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; FLAVANONES; GENES, MYC; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; MICE; MICE, TRANSGENIC; NEUROBLASTOMA; RNA, MESSENGER; TRANSGLUTAMINASES;

EID: 84868195654     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2012.02.067     Document Type: Article

References (31)

1. J.M. Maris, M.D. Hogarty, R. Bagatell, and S.L. Cohn Neuroblastoma Lancet 369 2007 2106 2120
2. K.K. Matthay, J.G. Villablanca, and R.C. Seeger Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's cancer group N Engl J Med 341 1999 1165 1173
3. J.E. Bolden, M.J. Peart, and R.W. Johnstone Anticancer activities of histone deacetylase inhibitors Nat Rev Drug Discov 5 2006 769 784
4. P.A. Marks, and R. Breslow Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug Nat Biotechnol 25 2007 84 90
5. W.K. Kelly, and P.A. Marks Drug insight: histone deacetylase inhibitors - development of the new targeted anticancer agent suberoylanilide hydroxamic acid Nat Clin Pract Oncol 2 2005 150 157
6. R.W. Johnstone Histone-deacetylase inhibitors: novel drugs for the treatment of cancer Nat Rev Drug Discov 1 2002 287 299
7. T. Liu, A.E. Tee, and A. Porro Activation of tissue transglutaminase transcription by histone deacetylase inhibition as a therapeutic approach for myc oncogenesis Proc Natl Acad Sci USA 104 2007 18682 18687
8. L. Lorand, and R.M. Graham Transglutaminases: crosslinking enzymes with pleiotropic functions Nat Rev Mol Cell Biol 4 2003 140 156
9. S.E. Iismaa, B.M. Mearns, L. Lorand, and R.M. Graham Transglutaminases and disease: Lessons from genetically engineered mouse models and inherited disorders Physiol Rev 89 2009 991 1023
10. M.A. Antonyak, J.M. Jansen, and A.M. Miller Two isoforms of tissue transglutaminase mediate opposing cellular fates Proc Natl Acad Sci USA 103 2006 18609 18614
11. B.A. Citron, Z. Suo, and K. SantaCruz Protein crosslinking, tissue transglutaminase, alternative splicing and neurodegeneration Neurochem Int 40 2002 69 78
12. B.M. Fraij, P.J. Birckbichler, M.K. Patterson Jr., K.N. Lee, and R.A. Gonzales A retinoic acid-inducible mrna from human erythroleukemia cells encodes a novel tissue transglutaminase homologue J Biol Chem 267 1992 22616 22623
13. A.E. Tee, G.M. Marshall, and P.Y. Liu Opposing effects of two tissue transglutaminase protein isoforms in neuroblastoma cell differentiation J Biol Chem 285 2010 3561 3567
14. G.M. Marshall, S. Gherardi, and N. Xu Transcriptional upregulation of histone deacetylase 2 promotes myc-induced oncogenic effects Oncogene 29 2010 5957 5968
15. G.M. Marshall, P.Y. Liu, and S. Gherardi Sirt1 promotes n-myc oncogenesis through a positive feedback loop involving the effects of mkp3 and erk on n-myc protein stability PLoS Genet 7 2011 e1002135
16. G.E. Begg, S.R. Holman, and P.H. Stokes Mutation of a critical arginine in the gtp-binding site of transglutaminase 2 disinhibits intracellular cross-linking activity J Biol Chem 281 2006 12603 12609
17. P. Reddy, Y. Maeda, and K. Hotary Histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect Proc Natl Acad Sci USA 101 2004 3921 3926
18. S. Kanno, A. Tomizawa, and T. Hiura Inhibitory effects of naringenin on tumor growth in human cancer cell lines and sarcoma s-180-implanted mice Biol Pharm Bull 28 2005 527 530
19. S. Kuljaca, T. Liu, and A.E. Tee Enhancing the anti-angiogenic action of histone deacetylase inhibitors Mol Cancer 6 2007 68
20. T. Liu, P.Y. Liu, and A.E. Tee Over-expression of clusterin is a resistance factor to the anti-cancer effect of histone deacetylase inhibitors Eur J Cancer 45 2009 1846 1854
21. W.R. Greco, G. Bravo, and J.C. Parsons The search for synergy: a critical review from a response surface perspective Pharmacol Rev 47 1995 331 385
22. Y. Yokoyama, M. Dhanabal, A.W. Griffioen, V.P. Sukhatme, and S. Ramakrishnan Synergy between angiostatin and endostatin: Inhibition of ovarian cancer growth Cancer Res 60 2000 2190 2196
23. H. Miayake, A. Tolcher, and M.E. Gleave Chemosensitization and delayed androgen-independent recurrence of prostate cancer with the use of antisense bcl-2 oligodeoxynucleotides J Natl Cancer Inst 92 2000 34 41
24. G.E. Begg, L. Carrington, and P.H. Stokes Mechanism of allosteric regulation of transglutaminase 2 by gtp Proc Natl Acad Sci USA 103 2006 19683 19688
25. A. Lentini, C. Forni, B. Provenzano, and S. Beninati Enhancement of transglutaminase activity and polyamine depletion in b16-f10 melanoma cells by flavonoids naringenin and hesperitin correlate to reduction of the in vivo metastatic potential Amino Acids 32 2007 95 100
26. A.J. Burgess, S. Pavey, and R. Warrener Up-regulation of p21(waf1/cip1) by histone deacetylase inhibitors reduces their cytotoxicity Mol Pharmacol 60 2001 828 837
27. Q. Ruan, J. Tucholski, S. Gundemir, and G.V. Johnson Voll The differential effects of r580a mutation on transamidation and gtp binding activity of rat and human type 2 transglutaminase Int J Clin Exp Med 1 2008 248 259
28. G. Ekambaram, P. Rajendran, V. Magesh, and D. Sakthisekaran Naringenin reduces tumor size and weight lost in n-methyl-n′-nitro-n- nitrosoguanidine-induced gastric carcinogenesis in rats Nutr Res 28 2008 106 112
29. D. Sabarinathan, P. Mahalakshmi, and A.J. Vanisree Naringenin, a flavanone inhibits the proliferation of cerebrally implanted c6 glioma cells in rats Chem Biol Interact 189 2011 26 36
30. P. Torricelli, P. Ricci, B. Provenzano, A. Lentini, and C. Tabolacci Synergic effect of alpha-tocopherol and naringenin in transglutaminase-induced differentiation of human prostate cancer cells Amino Acids 41 2010 1207 1214
31. U.J. Jung, H.J. Kim, and J.S. Lee Naringin supplementation lowers plasma lipids and enhances erythrocyte antioxidant enzyme activities in hypercholesterolemic subjects Clin Nutr 22 2003 561 568